Glenmark Pharmaceuticals Ltd. has successfully secured the final approval from the United States Food & Drug Administration (U.S. FDA) for its Apremilast Tablets in 10 mg, 20 mg, and 30 mg dosages. This approval allows Glenmark to market the generic counterpart of Amgen Inc.’s Otezla Tablets. Recent IQVIA sales figures reveal that the market for […]
Otezla FDA approval : US biotech company Celgene has bagged approval from the US Food and Drug Administration (FDA) for Otezla (apremilast) for the treatment of oral ulcers associated with Behcet’s Disease in adults. The approved dosage of the oral, selective inhibitor of phosphodiesterase 4 (PDE4) is 30mg twice daily. According to Celgene, Otezla is […]
Bristol-Myers Squibb has reached a definitive agreement to acquire Celgene Corporation in a monumental cash-and-stock deal worth approximately $74 billion. This acquisition will merge two pharmaceutical giants into a specialty biopharma company focused on cutting-edge therapies for cancer, cardiovascular disease, and immunological conditions. Details of the Bristol-Myers Squibb Celgene merger Under the terms of the […]